tailieunhanh - Báo cáo y học: "Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors. | Annals of General Psychiatry BioMed Central Open Access Case report Fluvoxamine monotherapy for psychotic depression the potential role of sigma-1 receptors Tsutomu Furuse 1 and Kenji Hashimoto2 Address Department of Psychiatry Asahikawa Red Cross Hospital Asahikawa Japan and 2Division of Clinical Neuroscience Chiba University Center for Forensic Mental Health Chiba Japan Email Tsutomu Furuse - furuse@ Kenji Hashimoto - hashimoto@ Corresponding author Published 21 December 2009 Received 10 November 2009 Annals of General Psychiatry 2009 8 26 doi l744-859X-8-26 Accepted 21 December 2009 This article is available from http content 8 1 26 2009 Furuse and Hashimoto licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Psychotic depression is a clinical subtype of major depressive disorder. A number of clinical studies have demonstrated the efficacy of the combination of an antidepressant for example a tricyclic antidepressant or selective serotonin reuptake inhibitor SSRI and an atypical antipsychotic or electroconvulsive therapy in treating psychotic depression. In some cases the clinician or patient may prefer to avoid antipsychotic drugs altogether because of the risk of extrapyramidal side effects EPS in patients with psychotic depression treated with these drugs. Methods We report five cases where fluvoxamine monotherapy was effective in the patients with psychotic depression. Results The scores on the Hamilton Depression HAM-D scale and the Brief Psychiatric Rating Scale BPRS in the five patients with psychotic depression were reduced after fluvoxamine monotherapy. Conclusion Doctors should consider fluvoxamine monotherapy as an .